• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email
    SC 13G/A 1 kalv1015242sc13ga3.htm AMENDMENT NO. 3

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    KalVista Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

     

    483497103

    (CUSIP Number)

     

     

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 2 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    4,321,547

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    4,321,547

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,321,547

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

     

    12

    type of reporting person

     

    OO

     

     

     Page 2 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 3 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    4,321,547

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    4,321,547

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,321,547

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

     

    12

    type of reporting person

     

    IN

     

     

     Page 3 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 4 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    3,366,547

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    3,366,547

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,366,547

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    7.78%

     

    12

    type of reporting person

     

    pN

     

     

     Page 4 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 5 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS III, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    855,000

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    855,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    855,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    1.98%

     

    12

    type of reporting person

     

    CO

     

     

     Page 5 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 6 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS IV, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    100,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    100,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    100,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.23%

     

    12

    type of reporting person

     

    CO

     

     

     Page 6 of 10 pages 
     

     

    Item 1(a).Name of Issuer:

     

    KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    55 Cambridge Parkway, Suite 901E, Cambridge, MA 02142

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and the Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations which are indirectly wholly owned by Tang Capital Partners.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 483497103

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 4,321,547 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III, Tang Capital Partners IV and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 4,321,547 shares of the Issuer’s Common Stock.

     

     Page 7 of 10 pages 
     

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III, Tang Capital Partners IV and Tang Capital Management.

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 3,366,547 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Partners III. Tang Capital Partners III beneficially owns 855,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners III shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Partners IV. Tang Capital Partners IV beneficially owns 100,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners IV shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 43,215,472 shares of Common Stock outstanding as of August 30, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on September 5, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 9.99%
    Kevin Tang 9.99%
    Tang Capital Partners 7.78%
    Tang Capital Partners III 1.98%
    Tang Capital Partners IV 0.23%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 4,321,547 shares
    Kevin Tang 4,321,547 shares
    Tang Capital Partners 3,366,547 shares
    Tang Capital Partners III 855,000 shares
    Tang Capital Partners IV 100,000 shares

     

     Page 8 of 10 pages 
     

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 4,321,547 shares
    Kevin Tang 4,321,547 shares
    Tang Capital Partners 3,366,547 shares
    Tang Capital Partners III 855,000 shares
    Tang Capital Partners IV 100,000 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 9 of 10 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: November 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL PARTNERS III, INC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  

     

     

    TANG CAPITAL PARTNERS IV, INC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 10 of 10 pages

     

     

     

    Get the next $KALV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with t

      5/2/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a

      4/30/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

      -Up to $24 million in upfront and milestone payments, plus royalties- -Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity- -Kaken brings regional expertise and proven track record in commercializing innovative therapies- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment o

      4/8/25 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Financials

    Live finance-specific insights

    See more
    • KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

      – Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

      2/13/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      4/11/25 5:22:07 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/14/25 7:45:15 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/11/25 7:51:08 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    See more

    $KALV
    SEC Filings

    See more

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • KalVista Appoints Jeb Ledell as Chief Operating Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

      12/16/24 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

      11/26/24 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Appoints Brian Piekos as Chief Financial Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join

      9/10/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      4/8/25 7:30:22 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by KalVista Pharmaceuticals Inc.

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/17/25 4:01:13 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/12/25 4:41:06 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      4/11/25 5:22:07 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 15,625 shares and sold $79,828 worth of shares (6,669 units at $11.97), increasing direct ownership by 3% to 287,811 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      3/10/25 6:43:21 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $23,988 worth of shares (2,394 units at $10.02), increasing direct ownership by 3% to 102,940 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/25/25 8:37:22 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 4:00:06 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 3:57:49 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

      SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 12:02:33 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

      JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

      1/31/25 7:03:28 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on KalVista Pharmaceuticals with a new price target

      TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      1/7/25 7:55:33 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on KalVista Pharmaceuticals with a new price target

      BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/18/24 7:36:39 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care